About Us

Who We Are

Established in 2013, OBiO Technology（Shanghai）Corp.,Ltd.（Stock：688238）is a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) in cell and gene therapy, offering comprehensive solutions; provides a range of technical services for the field of Regenerative Medicine and Anti-aging(Life&Health CDMO), include cell preparation, production of recombinant proteins/exosomes, and cell storage. Guided by our mission“ Enable Cell and Gene Therapy for Better Lives”, We are dedicated to delivering top-tier services globally. From bench to clinic, we are committed to advancing your product and benefiting populations worldwide.


As OBiO Technology swiftly evolves, adheres to the philosophy of "Integrating our resources to serve life sciences."  Every OBiOers are immersed in “Customer Focus、Efficient Execution、 Excellence、Innovation、Integrity ”，It has grown into a high-tech enterprise integrating three development directions of basic Contract Research Organization (CRO)，Contract Development and Manufacturing Organization (CDMO) in cell and gene therapy, and Regenerative Medicine (Life&Health CDMO).

History
2021

  • Successfully reviewed for the IPO in STAR Market

  • GMP platform expanded to more than 10000 ㎡ (107,639 ft²)

  • Multiple phase II clinical studies contracted

  • AAVneO® vector screening campaign launched, several innovative vectors preliminarily identified

2022

  • Listed as the first Chinese CGT CDMO in STAR Market on March 22

  • The company’s US branch, OBiO Tech., founded for expanding business outside China

2023

  • Lingang CGT GMP production base (Floorage: 80,000m2) commissioned on April 21

  • By 23H1, OBiO had helped its clients to get a total of 25 IND approval letters (8 of which were from FDA)

2024

  • Leverage the Power of Regenerative Medicine to Contribute Life & Health

Future

  • Becoming a leading multi-service provider in biopharmaceutical industry

2013

  • OBiO founded

2014

  • The acquisition of Neuron Biotech Co., Ltd. (which has become a wholly owned subsidiary of OBiO after the acquisition) laid down a solid foundation for OBiO as a leading AAV service provider

  • R&D of a number of gene therapy vectors and CRO service started

2015

  • Shareholding reform and Round A equity financing completed

  • Engaged in the first industry-academy-research strategic cooperation with Chinese Academy of Medical Sciences

2016

  • Listed in the National Equities Exchange And Quotations(NEEQ) system

  • OBiO Zhangjiang Integrated R&D Building (Floorage: 5000 ㎡) commissioned

2017

  • Viral vector GLP pilot-scale platform constructed and commissioned

  • Entered into an agreement with GE Medical for a global strategic cooperation in gene therapy research as a step towards business expansion into gene therapy CDMO sector

2018

  • The first OBiO CDMO project for IND submission of gene therapies (will be) launched

2019

  • OBiO Intelli-M (Shanghai) Gene Technology Co., Ltd., a subsidiary of OBiO, was founded;

  • Successfully delisted from the National Equities Exchange And Quotations(NEEQ) system

  • OBiO GMP production platform (Floorage: 5000 m2) constructed and commissioned

2020

  • Round 4 fund-raising completed

  • GMP platform expanded to about 7000 m² (75,347 ft²)

  • Construction of Lingang Precision Medicine Industry Base started

  • Accredited to be cGMP-compliant in an audit by a third-party Notified Body



Facilities
Lin-Gang Free-Trade Zone
OBiO Intelli-M
Process Development Characterization. Clinical and Commercial Manufacturing. Facility for Global Supply. 77,000 m² (828,821 ft²).
Read More
International Medical Park
PINE Site
Process and Analytical Method Development. Pre-clinical and Clinical Manufacturing. Three-building campus. 10,000 m² (107,639 ft²).
Read More
Intelligent Medical Industrialization Base
· The only 77,000 m² (828,821 ft²) scale GMP-compliant facility in the world
· Gene cell therapy commercial production service base
LARGE
·30+ gene cell therapy production lines
·Large-scale multi-option prokaryotic production capacity
·20 cell therapy product manufacturing lines
·50-2000L comprehensive and flexible viral vector manufacturing processes
·Filling and lyophilizing platform for manufacturing multiple dosage forms
·From DNA to IND to NDA
COMPREHENSIVE
· Single-use process vector production line
· Single-use process prokaryocyteculture production line
· Filling and lyophilizing-integrated innovative filling system
· Positive sample cell therapy product manufacturing line
INNOVATIVE
· Digitization and intelligentification-based mechanical arm material charging system
· Automatic dispensing system
· Automatic sample storage system in liquid nitrogen
· Chip-based automatic management of cleanroom suits
· Remote electronic signature system
· Full-cycle visualization-based project management
· Full-process business service requirements
INTELLIGENT
" F-A-S-T " commitment: At OBiO Technology, your gene therapy products will be manufactured faster and better
Our commitment
Request Now
© OBiO Tech, Inc. All Rights Reserved